checkAd

    DGAP-News  597  0 Kommentare MOLOGEN completes portfolio review: shift from research to product- and market-oriented company

    DGAP-News: MOLOGEN AG / Key word(s): Strategic Company Decision
    MOLOGEN completes portfolio review: shift from research to product- and
    market-oriented company

    09.06.2016 / 11:38
    The issuer is solely responsible for the content of this announcement.

    ---------------------------------------------------------------------------

    Press Release N 8 / 2016 of 06/09/2016

    MOLOGEN completes portfolio review: shift from research to product- and
    market-oriented company

    - "Next Level" of corporate development: strategy program with strong
    product and market orientation on key projects

    - Focus on lead product lefitolimod (MGN1703) and next-generation
    technology EnanDIM(R)

    - Streamlining of company organization

    - Commercialization activities to be stepped up via out-licensing

    Berlin, 9 June 2016 - Today, Berlin-based biotechnology company MOLOGEN
    (ISIN DE0006637200; Frankfurter Stock Exchange Prime Standard: MGN)
    presented its "Next Level" program which is based on a strategic portfolio
    review and envisages greater product and market orientation. The
    realignment and associated further development of the company's
    organization structure is intended to help MOLOGEN reach the next level of
    its development from a research-focused biotech company toward a product
    oriented one. The company will be focused more strongly than before on
    products which are no longer at the basic research stage and are already
    closer to reaching the market. The strategy program includes a
    concentration of the further development activities centered on the lead
    product, the cancer immunotherapy lefitolimod and next-generation molecules
    EnanDIM(R), along with an acceleration of the commercialization of these
    products.

    In contrast, MOLOGEN plans to shelve any further development of the
    compound MGN1601, a cell-based therapeutic vaccine against renal cancer,
    for the time being. In the event of lefitolimod products or the entire
    lefitolimod product group being successfully out-licensed, MGN1601 would be
    a suitable foundation from which to continue the business model based on an
    attractive next-generation clinical product which has moved beyond the
    basic research stage. The non-viral vector system MIDGE(R) is to be sold or
    spun off, along with the corresponding compounds.

    In addition, the new strategy includes the adjustment of the organization
    structures to the company's new stage of development. In particular,
    preconditions for a potential market entry will be created, initially of
    the lead product lefitolimod. These include, for example, ensuring
    sufficient production capacity by outsourcing production to subcontractors
    and consequently closing internal production capacity. In view of the
    Seite 1 von 4


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News MOLOGEN completes portfolio review: shift from research to product- and market-oriented company DGAP-News: MOLOGEN AG / Key word(s): Strategic Company Decision MOLOGEN completes portfolio review: shift from research to product- and market-oriented company 09.06.2016 / 11:38 The issuer is solely responsible for the content of this announcement. …